Company data sheet · Cardinal Health
Cardinal Health, from its filings.
- Industry
- Drugs, Proprietaries & Druggists' Sundries
- Headquarters
- United States
- Ticker
- CAH (NYSE)
- Sources
- SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 1, 2026
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $122 billion | $1.4 billion | |
| 2017 | $130 billion | $1.3 billion | |
| 2018 | $137 billion | $0.3 billion | |
| 2019 | $146 billion | $1.4 billion | |
| 2020 | $153 billion | −$3.7 billion | |
| 2021 | $162 billion | $0.6 billion | |
| 2022 | $181 billion | −$0.9 billion | |
| 2023 | $205 billion | $0.3 billion | |
| 2024 | $227 billion | $0.9 billion | |
| 2025 | $223 billion | $1.6 billion | |
| 2026 | $254 billion | $1.7 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 56 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (33 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 31 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.